Slide 1: AI-Powered, Portable Brain MRI – Corporate Investor Deck October 2025
Exhibit 99.2 AI-POWERED, PORTABLE BRAIN MRI The Swoop® Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck – October 2025 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, I
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe from time to time in Company’s filings with the Securities and Exchange Commission (the harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of “SE
Slide 3: Who is Hyperfine?
Who is Hyperfine? First FDA-cleared, AI-powered portable MR brain imaging system with strong proprietary technology, accessible across multiple sites of care from ICU, to offices and community settings, with compelling clinical and economic value proposition 1 $6B+ Market Opportunity . Early commerc
Slide 4: MRI is the Clinical Gold Standard, But Capacity and Access Are Limited
MRI is the Clinical Gold Standard, But Capacity and Access Are Limited The MRI You Know The MRI You Wish For Significantly less expensive, no High-cost and complex site shielding or siting required. requirements limit access Available at any healthcare facility Need for highly trained No dedicated p
Slide 5: Large Market Potential Bringing MRI to Multiple Sites of Care
Large Market Potential Bringing MRI to Multiple Sites of Care 1 Sizeable and Growing US TAM Through New Sites of Care $1.5B $6B+ $16B+ Outpatient Settings Community Settings Inpatient Settings 2025+ 2026+ 2023+ 2 Emergency departments Urgent care facilities Adult critical care 4,000+ 10,000+ Neurolo
Slide 6: Swoop System Powered by Optive AI Software
1 Swoop System Powered by Optive AI Software First mover advantage with Commercial in the US hospital and proprietary position (~200 office markets through direct sales patents) across multiple fields of channel use Global footprint through AI-enabled and a leading distributors and partnership with
Slide 7: Clinical Evidence Driving Market Expansion
Clinical Evidence Driving Market Expansion FUELING COMMERCIAL ADOPTION, SITE OF CARE ENTRY, AND UTILIZATION ACROSS HOSPITAL AND OUTPATIENT SETTINGS ACTION PMR — Stroke Triage & SAFE PMR — Complete! 80+ Diagnosis: ~90% sensitivity in Observed 100% of ischemic 1 infarct detection and bedside Peer even
Slide 8: The Swoop System Transforms and Expands the Reach of Brain Imaging
The Swoop System Transforms and Expands the Reach of Brain Imaging Diagnostic Images Captured in Portable, Compact Design Goes Simplified Set Up and Scanning for Directly to the Patient Broad Usability Multiple Sites of Care USING THE SWOOP SYSTEM IMPROVES MRI CAPACITY AND ACCESS WITH MEANINGFUL CLI
Slide 9: AI-Enabled Imaging Software
AI-Enabled Imaging Software Advanced, AI-driven image reconstruction to ultra-low field MRI—unlocking clearer images at lower field strengths Reduces noise and blur with deep learning, enhances image clarity and consistency, provides sharper anatomical detail to support confident diagnoses at the po
Slide 10: Image Quality Approaching Conventional MRI
Image Quality Approaching Conventional MRI OPTIVE AI IS HYPERFINE'S 10TH GENERATION AI-POWERED SOFTWARE IN 5 YEARS Proprietary Hardware, Software, and AI Deep Learning Innovation SWOOP SYSTEM EARLY DAYS Swoop System Powered by 1.5 T Conventional MRI (CIRCA 2016) Optive AI Software (2025) vs Sources:
Slide 11: June 2, 2025
June 2, 2025 11 PROPERTY OF HYPERFINE. ©2025. All rights reserved.
Slide 12: Strong Market Response to Recent Launches of Next-Gen Swoop System and Optive AI Software
Strong Market Response to Recent Launches of Next-Gen Swoop System and Optive AI Software This sleek, innovative redesign of the Swoop system is a transformational advance for the emerging field of portable MR imaging. …But the real breakthrough lies in how the hardware and software work together to
Slide 13: Growth Strategy
Growth Strategy Broad Indication and Versatile Technology Expected to Drive New Market Entrance and Adoption 20 24 20 25 Today US Critical Care: Continued Expansion Site of Care and Use Case Drivers Outpatient Market Entry SITE OF CARE AND PRIME ACTION PMR Economic Impact Data Emergency Dept. Entry
Slide 14: Hospital Business
Hospital Business • Compelling clinical utility in critical care, emergency triage, neurosurgery and neuro follow up in adults and peds • Strong economic value proposition o Swoop system scans qualify for existing reimbursement (CPT 70551) o Opportunity to increase revenue, cost savings and optimize
Slide 15: Office Business
Office Business • A typical neurologist orders 500–600 MRIs 1,2 annually for neurologic conditions such as headaches, dementia, tumor, MS, surgery follow-up • 90% of private neurology practices don’t have on- 3 site MR imaging • Affordable and appealing, plug-and-play Swoop system o No specialized s
Slide 16: Scalable Commercialization with US Direct Sales and Global Distribution Network
Scalable Commercialization with US Direct Sales and Global Distribution Network INSTALLED BASE 1 Over 190 Swoop Systems Globally DIRECT DISTRIBUTORS Dedicated Selling & 10+ Markets (2 FTE in Total) Implementation Teams (~15 FTE in Total) Healthy US Pricing & Recurring Revenue Extensive global footpr
Slide 17: Potential Revenue Opportunity
Potential Revenue Opportunity $100M US Swoop System Revenue For Every 1.5% Market Penetration Illustration of Estimated Potential US Device 1 Revenue With Site Penetration Growth Market Entry Hurdles Cleared Potential FDA Reimbursement Selling Sites of Care Cleared? Available? Leverage $400M (#) $30
Slide 18: Q3'25 Preliminary Unaudited Results
Q3’25 Preliminary 1 Unaudited Results Solid Financial Fundamentals “Tale of 2 Halves” Revenue and Realizing Operating Leverage 2 Key Takeaways REVENUE AND GROSS MARGIN CASH BURN • Next Generation Swoop System 25 Launched Mid’25 0.48 • New Technology, US Site of Care Gross Margin (%) Expansion and In
Slide 19: Q3'25 Preliminary Financials
Q3’25 Preliminary 1 Unaudited Results 1 Q3’25 Preliminary Financials Strong Revenue and Cash Burn Performance. Substantial Sequential Improvement 2 REVENUE CASH BURN $3.4 $10.1 +27% -19% $2.7 $8.1 +26% $2.1 -27% $5.9 1 1 Q1'25 Q2'25 Q3'25 Est. Q1'25 Q2'25 Q3'25 Est. Units 6 8 8 % Next Gen System 0%
Slide 20: Image Quality Driving Business Transformation Since Next Gen System Launch
Image Quality Driving Business Transformation Since Next Gen System Launch Commercial Outlook o US Hospital Pipeline Converted to Next Gen o Overwhelmingly Positive Feedback on System Image Quality and Radiology Community Ready to Support, Read, and Endorse o Majority of US Sales with Next Gen Swoop
Slide 21: Portable Ultra-Low Field Technology Creates Opportunities in New Anatomies
PORTABLE ULTRA-LOW FIELD TECHNOLOGY CREATES OPPORTUNITIES IN NEW ANATOMIES, INTERVENTIONS AND CAPABILITIES HYPERFINE PATENTS AND KNOW-HOW ARE WELL POSITIONED TO DELIVER IN MULTIPLE MARKETS WITH ADDITIONAL GROWTH AND VALUE-ADDED SERVICES Future Next Now Mobile for acute care Mobile brain health Expan
Slide 22: Leadership Team With Proven Track Record of Success
Leadership Team With Proven Track Record of Success Maria Sainz Brett Hale Tom Teisseyre, PhD President and Chief Chief Administrative Officer Chief Operating Officer Executive Officer and Chief Financial Officer Rafael Donnay Rob Fasciano, PhD Senior Vice President of Edmond Knopp, MD Chief Regulat
Slide 23: Who is Hyperfine?
Who is Hyperfine? First FDA-cleared, AI-powered portable MR brain imaging system with strong proprietary technology, accessible across multiple sites of care from ICU, to offices and community settings, with compelling clinical and economic value proposition 1 $6B+ Market Opportunity . Early commerc
Slide 24: FAYPERFINE.
FAYPERFINE.